196 related articles for article (PubMed ID: 33529168)
1. Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.
Gubitosi-Klug RA; Braffett BH; Hitt S; Arends V; Uschner D; Jones K; Diminick L; Karger AB; Paterson AD; Roshandel D; Marcovina S; Lachin JM; Steffes M; Palmer JP;
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33529168
[TBL] [Abstract][Full Text] [Related]
2. Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study.
McGee P; Steffes M; Nowicki M; Bayless M; Gubitosi-Klug R; Cleary P; Lachin J; Palmer J;
Diabet Med; 2014 Oct; 31(10):1264-8. PubMed ID: 24836354
[TBL] [Abstract][Full Text] [Related]
3. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
[TBL] [Abstract][Full Text] [Related]
4. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Steffes MW; Sibley S; Jackson M; Thomas W
Diabetes Care; 2003 Mar; 26(3):832-6. PubMed ID: 12610045
[TBL] [Abstract][Full Text] [Related]
5. High residual C-peptide likely contributes to glycemic control in type 1 diabetes.
Rickels MR; Evans-Molina C; Bahnson HT; Ylescupidez A; Nadeau KJ; Hao W; Clements MA; Sherr JL; Pratley RE; Hannon TS; Shah VN; Miller KM; Greenbaum CJ;
J Clin Invest; 2020 Apr; 130(4):1850-1862. PubMed ID: 31895699
[TBL] [Abstract][Full Text] [Related]
6. Residual β cell function and monogenic variants in long-duration type 1 diabetes patients.
Yu MG; Keenan HA; Shah HS; Frodsham SG; Pober D; He Z; Wolfson EA; D'Eon S; Tinsley LJ; Bonner-Weir S; Pezzolesi MG; King GL
J Clin Invest; 2019 Jul; 129(8):3252-3263. PubMed ID: 31264968
[TBL] [Abstract][Full Text] [Related]
7. A little help from residual β cells has long-lasting clinical benefits.
Lam A; Dayan C; Herold KC
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33529163
[TBL] [Abstract][Full Text] [Related]
8. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview.
Nathan DM;
Diabetes Care; 2014; 37(1):9-16. PubMed ID: 24356592
[TBL] [Abstract][Full Text] [Related]
9. Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents.
Sørensen JS; Johannesen J; Pociot F; Kristensen K; Thomsen J; Hertel NT; Kjaersgaard P; Brorsson C; Birkebaek NH;
Diabetes Care; 2013 Nov; 36(11):3454-9. PubMed ID: 23990516
[TBL] [Abstract][Full Text] [Related]
10. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA
Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA;
Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221
[TBL] [Abstract][Full Text] [Related]
11. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes.
Picardi A; Visalli N; Lauria A; Suraci C; Buzzetti R; Merola MK; Manfrini S; Guglielmi C; Gentilucci UV; Pitocco D; Crinò A; Bizzarri C; Cappa M; Pozzilli P
Horm Metab Res; 2006 Oct; 38(10):668-72. PubMed ID: 17075776
[TBL] [Abstract][Full Text] [Related]
12. Impact of C-Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM.
Zenz S; Mader JK; Regittnig W; Brunner M; Korsatko S; Boulgaropoulos B; Magnes C; Raml R; Narath SH; Eller P; Augustin T; Pieber TR
J Clin Endocrinol Metab; 2018 Apr; 103(4):1408-1417. PubMed ID: 29408994
[TBL] [Abstract][Full Text] [Related]
13. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus.
Sousa GR; Pober D; Galderisi A; Lv H; Yu L; Pereira AC; Doria A; Kosiborod M; Lipes MA
Circulation; 2019 Feb; 139(6):730-743. PubMed ID: 30586738
[TBL] [Abstract][Full Text] [Related]
14. Temporal dynamics of serum let-7g expression mirror the decline of residual beta-cell function in longitudinal observation of children with type 1 diabetes.
Małachowska B; Wyka K; Nowicka Z; Bartłomiejczyk MA; Młynarski W; Fendler W
Pediatr Diabetes; 2018 Dec; 19(8):1407-1415. PubMed ID: 30259606
[TBL] [Abstract][Full Text] [Related]
15. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study.
Gubitosi-Klug RA; Braffett BH; White NH; Sherwin RS; Service FJ; Lachin JM; Tamborlane WV;
Diabetes Care; 2017 Aug; 40(8):1010-1016. PubMed ID: 28550194
[TBL] [Abstract][Full Text] [Related]
16. Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.
Thivolet C; Marchand L; Chikh K
Diabetologia; 2019 Apr; 62(4):593-597. PubMed ID: 30612138
[TBL] [Abstract][Full Text] [Related]
17. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.
DCCT/EDIC research group
Lancet Diabetes Endocrinol; 2014 Oct; 2(10):793-800. PubMed ID: 25043685
[TBL] [Abstract][Full Text] [Related]
18. Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.
Hao W; Gitelman S; DiMeglio LA; Boulware D; Greenbaum CJ;
Diabetes Care; 2016 Oct; 39(10):1664-70. PubMed ID: 27422577
[TBL] [Abstract][Full Text] [Related]
19. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study.
Fährmann ER; Adkins L; Loader CJ; Han H; Rice KM; Denvir J; Driscoll HK
Diabetes Res Clin Pract; 2015 Feb; 107(2):280-9. PubMed ID: 25467622
[TBL] [Abstract][Full Text] [Related]
20. [Autoimmune insulitis in patients with type 2 diabetes mellitus A randomized clinical trial in hospitalized patients].
Martinka E; Rončáková M; Mišániková M; Davani A
Vnitr Lek; 2016; 62(7-8):521-33. PubMed ID: 27627073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
